JP2021073259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021073259A5 JP2021073259A5 JP2021012440A JP2021012440A JP2021073259A5 JP 2021073259 A5 JP2021073259 A5 JP 2021073259A5 JP 2021012440 A JP2021012440 A JP 2021012440A JP 2021012440 A JP2021012440 A JP 2021012440A JP 2021073259 A5 JP2021073259 A5 JP 2021073259A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- salt according
- salt
- inflammatory
- xrpd pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 15
- 208000027866 inflammatory disease Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 201000004810 Vascular dementia Diseases 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- JHGGOTFKWARTGB-UHFFFAOYSA-N CS(=O)(=O)O.C(C1=CN=CC=C1)(=O)O Chemical compound CS(=O)(=O)O.C(C1=CN=CC=C1)(=O)O JHGGOTFKWARTGB-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000018093 autoimmune cholangitis Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507036.0A GB201507036D0 (en) | 2015-04-24 | 2015-04-24 | Crystalline enzyme inhibitor compound |
| GB1507036.0 | 2015-04-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550912A Division JP2018513139A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ酵素阻害剤としての結晶性化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021073259A JP2021073259A (ja) | 2021-05-13 |
| JP2021073259A5 true JP2021073259A5 (enExample) | 2021-08-12 |
Family
ID=53488634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550912A Pending JP2018513139A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ酵素阻害剤としての結晶性化合物 |
| JP2021012440A Withdrawn JP2021073259A (ja) | 2015-04-24 | 2021-01-28 | セミカルバジド感受性アミンオキシダーゼ酵素阻害剤としての結晶性化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550912A Pending JP2018513139A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ酵素阻害剤としての結晶性化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10369139B2 (enExample) |
| EP (1) | EP3286189B1 (enExample) |
| JP (2) | JP2018513139A (enExample) |
| KR (1) | KR20170139046A (enExample) |
| CN (1) | CN107531701A (enExample) |
| AU (1) | AU2016252236A1 (enExample) |
| BR (1) | BR112017020046A2 (enExample) |
| CA (1) | CA2979157A1 (enExample) |
| EA (1) | EA033064B1 (enExample) |
| GB (1) | GB201507036D0 (enExample) |
| HK (1) | HK1249907A1 (enExample) |
| IL (1) | IL254154A0 (enExample) |
| MX (1) | MX2017013048A (enExample) |
| SG (1) | SG11201707868YA (enExample) |
| WO (1) | WO2016170352A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| GB201507031D0 (en) | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| GB201618029D0 (en) | 2016-10-25 | 2016-12-07 | Proximagen Ltd | New process |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141899A (en) | 1976-01-07 | 1979-02-27 | Societa' Farmaceutici Italia S.P.A. | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives |
| IT1098015B (it) | 1978-08-07 | 1985-08-31 | Farmaceutici Italia | Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati |
| US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| AU2002214505A1 (en) | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
| SE0004101D0 (sv) | 2000-11-09 | 2000-11-09 | Pharmacia Ab | New use |
| US20070066646A1 (en) | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
| EP3461499A1 (en) | 2006-06-07 | 2019-04-03 | The Board of Trustees of The Leland Stanford Junior University | Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures |
| MX2011002581A (es) * | 2008-09-16 | 2011-04-07 | Proximagen Ltd | Compuestos nuevos i. |
| CA2915163A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| HUE042625T2 (hu) | 2014-04-15 | 2019-07-29 | Pecsi Tudomanyegyetem | Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban |
| GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
| GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
-
2015
- 2015-04-24 GB GBGB1507036.0A patent/GB201507036D0/en not_active Ceased
-
2016
- 2016-04-22 US US15/567,549 patent/US10369139B2/en not_active Expired - Fee Related
- 2016-04-22 MX MX2017013048A patent/MX2017013048A/es unknown
- 2016-04-22 HK HK18109399.8A patent/HK1249907A1/zh unknown
- 2016-04-22 BR BR112017020046A patent/BR112017020046A2/pt not_active Application Discontinuation
- 2016-04-22 KR KR1020177032023A patent/KR20170139046A/ko not_active Withdrawn
- 2016-04-22 JP JP2017550912A patent/JP2018513139A/ja active Pending
- 2016-04-22 EP EP16718883.8A patent/EP3286189B1/en active Active
- 2016-04-22 EA EA201792122A patent/EA033064B1/ru not_active IP Right Cessation
- 2016-04-22 AU AU2016252236A patent/AU2016252236A1/en not_active Abandoned
- 2016-04-22 CN CN201680023291.3A patent/CN107531701A/zh active Pending
- 2016-04-22 SG SG11201707868YA patent/SG11201707868YA/en unknown
- 2016-04-22 WO PCT/GB2016/051120 patent/WO2016170352A1/en not_active Ceased
- 2016-04-22 CA CA2979157A patent/CA2979157A1/en not_active Abandoned
-
2017
- 2017-08-24 IL IL254154A patent/IL254154A0/en unknown
-
2021
- 2021-01-28 JP JP2021012440A patent/JP2021073259A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021073256A5 (enExample) | ||
| JP2023546125A5 (enExample) | ||
| FI4157832T3 (fi) | Glp-1r-agonistien suola- ja kidemuotoja ja niiden käyttötarkoituksia | |
| US10632085B2 (en) | Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts | |
| JP2012506368A5 (enExample) | ||
| CN103539795A (zh) | 阿哌沙班的多晶型及其制备方法 | |
| CN117362282B (zh) | Glp-1r激动剂的盐及其制备方法和应用 | |
| JP7436057B2 (ja) | ウパダシチニブのジ－ｐ－トルオイル－Ｌ－タートレートの結晶形 | |
| JP7836263B2 (ja) | トリアジン化合物の塩、その結晶形及び製造方法 | |
| WO2020020064A1 (zh) | 利用三光气安全制备匹莫范色林及其酒石酸盐的方法 | |
| JP2025143254A5 (enExample) | ||
| CN117417330A (zh) | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 | |
| JP2022160667A (ja) | アクリジニウム臭化物の製造方法 | |
| CN117417329A (zh) | 一种glp-1r激动剂的多晶型物及其制备方法与用途 | |
| TW201912656A (zh) | 舒更葡糖鈉之製備方法及其晶型 | |
| CN114127061A (zh) | (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式 | |
| US20260028332A1 (en) | Polymorphic form of glp-1r agonist, preparation method therefor and use thereof | |
| US20100210842A1 (en) | Process for preparing | |
| EP4065581B1 (en) | Process for the preparation (9s)-2-bromo-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepine | |
| TWI463981B (zh) | 異丁酸(1r*,2r*,4r*)-2-(2-{[3-(4,7-二甲氧基-1h-苯并咪唑-2-基)-丙基]-甲基-胺基}-乙基)-5-苯基-二環[2.2.2]辛-5-烯-2-基酯之鹽 | |
| CN101817819A (zh) | 用作抗抑郁药的5-烷氧基-四唑并[1,5-a]喹啉酮衍生物及其可药用盐 | |
| RU2023112071A (ru) | ТВЕРДЫЕ ФОРМЫ СОЛИ 2-((4-((S)-2-(5-ХЛОРПИРИДИН-2-ил)-2-МЕТИЛБЕНЗО[d][1,3]ДИОКСОЛ-4-ИЛ)ПИПЕРЕДИН-1-ИЛ)МЕТИЛ)-1-(((S)-ОКСЕТАН-2-ИЛ)МЕТИЛ)-1H-БЕНЗО[d]ИМИДАЗОЛ-6-КАРБОНОВОЙ КИСЛОТЫ С 1,3-ДИГИДРОКСИ-2-(ГИДРОКСИМЕТИЛ)ПРОПАН-2-АМИНОМ | |
| HK40118695A (en) | Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof | |
| HK40118695B (en) | Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof | |
| CN107383055A (zh) | 硫酸氢氯吡格雷的合成方法 |